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ABSTRACT
Objectives: To investigate the efficacy and safety of
CS1002, an over-the-counter cough treatment
containing diphenhydramine, ammonium chloride and
levomenthol in a cocoa-based demulcent.
Design: A multicentre, randomised, parallel group,
controlled, single-blinded study in participants with
acute upper respiratory tract infection-associated cough.
Setting: 4 general practitioner (GP) surgeries and 14
pharmacies in the UK.
Participants: Participants aged ≥18 years who self-
referred to a GP or pharmacist with acute cough of
<7 days’ duration. Participant inclusion criterion was
cough severity ≥60 mm on a 0–100 mm visual
analogue scale (VAS). Exclusion criteria included
current smokers or history of smoking within the past
12 months (including e-cigarettes). 163 participants
were randomised to the study (mean participant age
38 years, 57% females).
Interventions: Participants were randomised to
CS1002 (Unicough) or simple linctus (SL), a widely
used cough treatment, and treatment duration was
7 days or until resolution of cough.
Main outcome measures: The primary analysis was
intention-to-treat (157 participants) and comprised
cough severity assessed using a VAS after 3 days’
treatment (prespecified primary end point at day 4).
Cough frequency, sleep disruption, health status
(Leicester Cough Questionnaire (LCQ-acute)) and cough
resolution were also assessed.
Results: At day 4 (primary end point), the adjusted
mean difference (95% CI) in cough severity VAS
between CS1002 and SL was −5.9 mm (−14.4 to 2.7),
p=0.18. At the end of the study (day 7) the mean
difference in cough severity VAS was −4.2 mm (−12.2
to 3.9), p=0.31. CS1002 was associated with a greater
reduction in cough sleep disruption (mean difference
−11.6 mm (−20.6 to 2.7), p=0.01) and cough
frequency (mean difference −8.1 mm (−16.2 to 0.1),
p=0.05) compared with SL. There was greater
improvement in LCQ-acute quality of life scores with
CS1002 compared with SL: mean difference (95% CI)
1.2 (0.05 to 2.36), p=0.04 after 5 days’ treatment. More
participants prematurely stopped treatment due to
cough improvement in the CS1002 group (24.4%)
compared with SL (10.7%; p=0.02). Adverse events
(AEs) were comparable between CS1002 (20.5%) and
SL (27.6%) and largely related to the study indication. 6
participants (7%) in the CS1002 group reduced the
dose of medication due to drowsiness/tiredness, which
subsequently resolved. These events were not reported
by participants as AEs.
Conclusions: Although the primary end point was not
achieved, CS1002 was associated with greater
reductions in cough frequency, sleep disruption and
improved health status compared with SL.
Trial registration number: EudraCT number
2014-004255-31.
INTRODUCTION
Approximately one in ﬁve people in the UK
suffer an acute cough over the winter1 and it
Strengths and limitations of this study
▪ A recent Cochrane systematic review of cough
medicines found no good evidence for or against
the effectiveness of over-the-counter medications
in acute cough.
▪ This is one of the largest multiple dosing, multi-
centre, randomised, controlled trials in partici-
pants with cough to date, and the first to recruit
participants seeking cough medicines at pharma-
cies and is therefore more likely to represent the
broader population with acute cough due to
upper respiratory tract infection.
▪ Participants were unselected for the category of
cough, and included a broad range of partici-
pants with self-reported dry, chesty and tickly
cough.
▪ The study was single-blinded because an active
control, simple linctus, was used as the com-
parator but it is possible that there may have
been greater differences in efficacy outcome
measures if an inactive placebo had been used.
▪ Our findings highlight the challenges of evaluat-
ing cough medicines in a rapidly improving con-
dition and will facilitate the design of future
studies of acute cough.
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is one of the most common reasons for consulting a
general practitioner (GP), at a cost to the National
Health Service (NHS) of ∼£2 billion per year.2–4
Although most acute coughs improve spontaneously,
many patients use over-the-counter (OTC) medicines. In
2014, £98.7 million was spent in the UK on OTC cough
treatments.5 OTC cough medicines include antitussives,
expectorants, mucolytics, antihistamines, decongestants
and numerous drug combinations.6 There is a lack of
data supporting the efﬁcacy of OTC medicines in the
treatment of acute cough associated with upper respira-
tory tract infection (URTI). In 2012, a Cochrane system-
atic review concluded there was no strong evidence for
or against their effectiveness.6 Methodological ﬂaws in
clinical trial design, paucity of placebo-controlled trials,
use of unvalidated outcome measures and inefﬁcacy of
medicines were some of the reasons for the poor evi-
dence base.
CS1002 is an OTC cough medicine that contains
three active ingredients: diphenhydramine, levomenthol
and ammonium chloride in a cocoa-based demulcent
preparation. Diphenhydramine is an antihistamine that
has been reported to reduce the heightened cough
reﬂex sensitivity in participants with cough associated
with an URTI.7 Menthol and eucalyptus have been
used for many centuries for treating coughs and
colds.8 Menthol is obtained from mint oils, mainly
peppermint, or made synthetically from coal tar. It has
a pungent odour that provides a cooling and soothing
effect in the mouth and throat and is often used to
relieve congestion.8 Menthol has also been reported to
inhibit cough reﬂex sensitivity compared with placebo.9
Ammonium chloride is an acid-forming salt that is
thought to exert an expectorant effect by loosening
sputum.10 The effectiveness and mode of action of
ammonium chloride remains controversial.10 The
cocoa-based demulcent preparation used in CS1002 is
more viscous than most available OTC cough medi-
cines. Demulcents are thought to reduce cough and
cold symptoms because of a soothing effect on the
mucus membrane.11 The aim of this study was to inves-
tigate the efﬁcacy of CS1002, an OTC cough medicine
for cough associated with URTI, in a randomised con-
trolled trial.
METHODS
Study design
This multicentre, randomised, parallel group, con-
trolled, single-blinded study was conducted in 4 GP sur-
geries and 14 pharmacies in the UK between 30
December 2014 and 9 May 2015. The control was a
widely used simple linctus (SL) medicine available for
acute cough in the UK. The investigators were blinded
to the nature of the investigational product by using
identical sealed packaging for both medicines.
Participants self-administered their assigned medication
outside the pharmacy or GP surgery.
Participants
Participants aged ≥18 years who self-referred themselves
to a GP or pharmacist with an acute cough of <7 days’
duration were recruited. Participant inclusion criterion
was a severity of at least 60 mm on a 0–100 mm visual
analogue scale (VAS). Participant exclusion criteria were
(1) participants with a chronic cough, (2) current or
history of smoking within the past 12 months (including
e-cigarettes), (3) participants with any relevant hospital
stay of >2 days within a 6-month period, (4) use of any
cough or cold treatment for the current cough episode,
including antibiotics, (5) productive cough with exces-
sive secretion, (6) use of ACE inhibitors medication.
Participant involvement
Participants were not involved in the design or conduct
of this study.
Ethics and trial registration
The trial protocol was registered prior to starting the
study in the publically available EudraCT database (ref-
erence: 2014-004255-31) and no protocol amendments
were made subsequently. All participants provided
written informed consent.
Randomisation
All participants considered eligible for study participa-
tion and who signed a consent form were given a
unique randomisation number based on a predeﬁned
computer-generated randomisation scheme correspond-
ing to a sealed medication pack that contained either
CS1002 (2×150 mL) or SL (2×150 mL). Participants
were allocated treatment using a block randomisation
with a block size of 4.
Study medication
Participants were randomised to one of the following
treatments:
▸ CS1002 (Unicough): diphenhydramine 14 mg/5 mL,
levomenthol 1.1 mg/5 mL and ammonium chloride
135 mg/5 mL in a cocoa-based demulcent
preparation.
▸ SL: citric acid monohydrate 125 mg/5 mL in a syrup
base.
Interventions
The participants were approached, screened, consented
and randomised during their initial consultation with
their GP or the pharmacist. Participants took their study
medication orally four times daily (5 mL in the morning,
5 mL at lunchtime, 10 mL at teatime and 10 mL at
bedtime) for up to 7 days. Participants were instructed to
take the medication regularly until the cough resolved.
Methods of evaluation
Participants completed their assessments and compli-
ance with medication in a daily diary. Each participant
received a tamper-evident unidentiﬁable patient pack
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which was only opened on leaving the site. On comple-
tion, the pack was returned in a resealed and unidentiﬁ-
able state. An independent data management
organisation was used for data entry and to manage
adverse event (AE) reporting. The investigators were
blinded to the assignment of treatment and to the
outcome assessments. The schedule of study visits is pre-
sented in ﬁgure 1. The participants were asked to com-
plete assessments at baseline (day 1) and then at the
same time of day from day 2–8. The study evaluated the
efﬁcacy of the study medications by assessing various
aspects of acute cough.12 Cough severity, frequency and
impact on sleep disruption in the previous 24 hours
were assessed using a VAS. Health-related quality of life
(HRQoL) was assessed using the Leicester Cough
Questionnaire for acute cough (LCQ-acute).3 13 The
LCQ is a valid and reliable health status measure of
acute cough in adults and is responsive to change. It
comprises 19 items divided into three domains (phys-
ical, psychological and social) and uses a seven-point
Likert response scale. A higher score indicates a better
health status. The LCQ is designed for self-
administration and takes <5 min to complete.3 14
Primary efficacy end point
The primary efﬁcacy end point was change from base-
line to day 4 (ie, after 3 complete days of treatment) in
cough severity on a 100 mm VAS (ranging from 0=no
cough to 100=worst cough ever).
Secondary efficacy end points
The following prespeciﬁed end points were evaluated:
(1) change from baseline in cough severity VAS at days 6
and 8; (2) change from baseline in cough frequency
and cough sleep disruption VAS at days 4, 6 and 8; (3)
time to resolution of cough symptoms, deﬁned as the
day at which cough severity VAS<17 mm (the threshold
considered to be of minimal severity and the minimally
important difference (MID) in acute cough);12 (4)
change from baseline in LCQ-acute score at days 4, 6
and 8.
Safety monitoring
Participants were advised to reduce the dose of medica-
tion if they experienced drowsiness, and to document
this in their daily diary. If drowsiness persisted, they were
advised to discontinue the medication. Participants were
advised to contact their doctor or a 24-hour help line if
they felt unwell. Safety was assessed in terms of the fre-
quency and severity of AEs occurring during the study
and this was recorded by the investigator.
Statistical analysis and sample size
The sample size calculation was based on a difference in
the change in cough severity VAS of 17 mm between par-
ticipants treated with CS1002 and SL. Evaluation of the
VAS in acute cough has suggested that the MID is
17 mm.12 It was estimated that ∼180 participants would
be required to achieve a power of 90% to detect a differ-
ence between the treatment groups of 17 mm, with an
SD of 35 mm.12
The primary analysis was conducted on the
intention-to-treat (ITT) population, comprising all ran-
domised participants who were treated with at least one
dose of study medication and provided a baseline and at
least one on-treatment assessment of cough severity. No
imputation was used for missing data (ie, only observed
data were used). A mixed model for repeated measures
analysis was used to compare the effect of study treat-
ments on cough parameters from baseline. The model
included effects for treatment group, day, pooled centre,
baseline cough severity, and treatment-by-day and
baseline-by-day cough severity interaction terms.
Residual plots and a normality test were used to assess
Figure 1 Study design. GP, general practitioner; LCQ-acute, Leicester Cough Questionnaire; VAS, visual analogue scale.
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normality. The results were also repeated for the per-
protocol set (PPS), deﬁned as participants in the ITT
population who did not have an important protocol vio-
lation. A sensitivity analysis was also conducted to assess
the robustness of the primary efﬁcacy results to the
method of handling missing data, using a last observa-
tion carried forward approach and a baseline observa-
tion carried forward approach for participants with no
on-treatment data. Parametric data were presented as
mean and either SD, SEM or 95% CIs. Statistical signiﬁ-
cance was deﬁned as p≤0.05. The proportions of partici-
pants with cough resolution were compared using a
stratiﬁed (by centre) Cochran-Mantel-Haenszel test.
Time-to-event analysis using a Cox proportional hazards
model stratiﬁed by centre was used to estimate a HR.
RESULTS
Participants
A total of 163 participants were randomised into the
study at 4 GP sites and 14 pharmacy sites. The reasons
for screening failures are shown in ﬁgure 2. The ITT
population comprised 157 participants (82 CS1002, 75
SL), and the PPS comprised 142 participants (75
CS1002, 67 SL; ﬁgure 2). The baseline characteristics of
both treatment groups were well matched (table 1). The
mean age of the participants was 38 years, 57% of parti-
cipants were female and 62% of participants were white
(34% Asian and 4% black). The groups were well
matched for the proportion of participants describing
the characteristics of their cough as dry (CS1002 50%;
SL 52%), chesty (CS1002 29%; SL 31%) or tickly
(CS1002 21%; SL 17%).
Figure 2 Trial CONSORT flow diagram. VAS, visual analogue scale.
Table 1 Participant demographic and baseline
characteristics
CS1002
n (%)
N=82
Simple linctus
n (%)
N=75
Gender (N (%))
Male 34 (42) 34 (45)
Female 48 (59) 41 (55)
Age (years)
Mean (SD) 38.5 (17.3) 38.2 (16.6)
Median (range) 31.5 (18, 75) 34.0 (18, 86)
Type of referral (N (%))
GP 30 (37) 27 (36)
Pharmacist 52 (63) 48 (64)
Smoking status (N (%))
Never smoked 64 (78) 54 (72)
Ex-smoker 18 (22) 21 (28)
Cough characteristics, mean (SD)
Cough duration (days) 3.0 (1.5) 3.1 (1.6)
Cough severity
VAS (mm)
80.4 (10.1) 81.6 (9.9)
Cough frequency
VAS (mm)
79.5 (16.1) 76.7 (15.5)
Cough sleep disruption
VAS (mm)
75.5 (23.2) 64.6 (29.2)
LCQ-acute scores, mean (SD)
Total score 10.8 (3.5) 11.4 (3.2)
Physical score 3.7 (1.2) 4.1 (1.1)
Psychological score 3.7 (1.2) 3.9 (1.1)
Social score 3.4 (1.4) 3.5 (1.3)
Based on ITT population.
GP, general practitioner; ITT, intention-to-treat; LCQ, Leicester
Cough Questionnaire; VAS, visual analogue scale (using a scale
of 0–100 mm).
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Exposure
Participants took CS1002 medication for a mean (SD) of
6.2 (2.1) days and SL medication for 6.6 (1.8) days. The
mean number of doses of study medication were 22.2
(8.7) for the CS1002 group and 23.7 (8.3) in the SL
group. The maximum number of medication doses pos-
sible during the study was 28. The weight of the bottles
of treatment returned at the end of study was planned
to be used to estimate compliance, excluding doses not
taken due to early termination from the study due to
recovery. The weight of medicine broadly agreed with
self-reported consumption stated by participants receiv-
ing CS1002, with a mean (SD) of 94% (17%) vs 94%
(18%) for participants receiving SL.
Primary efficacy end point
There was a clinically meaningful improvement in
cough severity VAS at day 4 in both groups (table 2 and
ﬁgure 3). The magnitude of the reduction in cough
severity score was greater in the CS1002 group compared
with the SL group but was not statistically signiﬁcant;
mean (95% CI) difference of −5.9 mm (−14.4 to 2.7),
p=0.18. The PPS and ITT sensitivity analyses with impu-
tations were also consistent with this ﬁnding (see online
supplementary ﬁle).
Secondary efficacy end points
Cough severity: There was a progressive decrease in cough
severity VAS over the study, with the CS1002 group report-
ing a greater reduction compared with the SL group
between days 3 and 7 (ﬁgure 3). The between group
changes in cough severity VAS did not achieve statistical
signiﬁcance (mean (95% CI) difference of −4.2 mm
(−12.2 to 3.9), p=0.31 at day 7; table 2 and ﬁgure 3).
Cough frequency: There was a greater reduction in cough
frequency VAS with CS1002 compared with SL at all time
points (ﬁgure 4). At Day 4, there was an −8.1 mm (95%
CI −16.2 to 0.1) greater reduction in cough frequency
VAS for CS1002 compared with SL (p=0.05; table 2 and
ﬁgure 4).
Cough resolution: By day 4, 29.3% of participants in the
CS1002 group had achieved cough resolution compared
with 17.3% in the SL group (p=0.08; table 2). There was
no signiﬁcant difference between the treatment groups
regarding median time taken to achieve cough reso-
lution (CS1002 6.5 days, SL 7.0 days, HR 1.300, p=0.20,
ﬁgure 5). In a post hoc analysis, 20 participants (24.4%)
Figure 3 Change in cough severity over time.
ITT, intention-to-treat.
Table 2 Analysis of key efficacy parameters at day 4
Key efficacy assessments CS1002 Simple linctus
Number of participants 82 75
Cough severity
Baseline value (mean±SD) 80.4 (10.1) 81.6 (9.9)
Change from baseline to day 4: mean ( 95% CI) −38.9 (−45.2 to −33.2) −32.8 (−39.6 to −27.0)
Adjusted mean difference (95% CI) −5.9 (−14.4 to 2.7)
p Value (between groups) p=0.18
Cough frequency
Baseline value (mean±SD) 79.5 (16.1) 76.7 (15.5)
Change from baseline to day 4: mean ( 95% CI) −40.7 (−46.0 to −34.6) −32.1 (−38.1 to −26.4)
Adjusted mean difference (95% CI) −8.1 (−16.2 to 0.1)
p Value (between groups) p=0.05
Cough resolution
Day 4 value (n, %) 24 (29.3%) 13 (17.3)
Difference (%) 12%
p Value (between groups) p=0.08
Sleep disruption
Baseline value (mean±SD) 75.5 (23.2) 64.6 (29.2)
Change from baseline to day 4; mean ( 95% CI) −42.8 (−46.9 to −34.4) −26.3 (−35.5 to −22.6)
Adjusted mean difference (95% CI) −11.6 (−20.6 to −2.7)
p Value (between groups) p=0.01
Based on intention-to-treat (ITT) population.
Negative values indicate a reduction in cough symptoms.
Adjusted mean difference, difference in between group differences.
Cough severity, frequency and sleep disruption measured on a visual analogue scale (0-100 mm) Bold signifies p values.
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in the CS1002 group and 10 (10.7%) in SL group
stopped treatment by day 4 due to improvement in
cough (p=0.02).
Sleep disruption: There was a greater reduction in sleep
disruption with CS1002 compared with SL at all time
points (ﬁgure 6). At day 4, the magnitude of reduction
in cough sleep disruption score was greater for the
CS1002 group than for the SL group, mean difference
of −11.6 mm (95% CI −20.6 to −2.7), p=0.01 (ﬁgure 6
and table 2). A summary of all VAS results is provided in
online supplementary ﬁgure S1.
Health-related quality of life: LCQ-acute total scores
increased over time for both treatment groups, indicat-
ing an improvement in HRQoL. At day 6, the magnitude
of the improvement was signiﬁcantly greater in the
CS1002 group compared with the SL group (mean dif-
ference 1.21 (95% CI 0.05 to 2.36), p=0.04; see online
supplementary ﬁgures S2 and S3).
Adverse events
AEs were reported for 17 participants (20.5%) in the
CS1002 group and 21 participants (27.6%) in the SL
group during the study (table 3). The AEs were gener-
ally indicative of the study indication or likely to be asso-
ciated with URTI, with the majority being mild or
moderate severity. Events classiﬁed as severe were only
seen in the SL treatment group, and comprised cough,
sneezing and joint swelling (all occurring in one partici-
pant each). No SAEs or deaths were reported. There
were no AEs of drowsiness reported during the study. Six
participants (7%) in the CS1002 group and no partici-
pants in the SL group reported in their diary that they
reduced the dose of medication due to drowsiness/tired-
ness. These events were not reported by the participants
as AE. Following the reduction of the dose of medica-
tion, there were no further reports of drowsiness or
tiredness.
Figure 4 Change in cough frequency over time. ITT,
intention-to-treat; MMRM, mixed model for repeated
measures.
Figure 5 Resolution of cough: cumulative percentage of participants. ITT, intention-to-treat; VAS, visual analogue scale.
Figure 6 Change in cough sleep disruption over time. ITT,
intention-to-treat; MMRM, mixed model for repeated
measures.
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DISCUSSION
This multicentre, randomised study compared the efﬁ-
cacy and safety of two OTC cough mixtures: CS1002 con-
taining diphenhydramine, ammonium chloride and
levomenthol in a cocoa-based demulcent preparation
versus SL containing citric acid monohydrate. This is
one of the largest multiple dosing, randomised con-
trolled trials in participants with URTI-associated cough
to date, and the ﬁrst to recruit participants seeking
cough medicines at pharmacies. The study did not
achieve a signiﬁcant reduction in primary end point
cough severity after 3 days of treatment, but there were
greater reductions in cough frequency and sleep disrup-
tion and resolution of cough in participants receiving
CS1002 compared with SL.
Our trial represents a signiﬁcant advance in the study
of URTI-associated cough for a number of reasons. A
Cochrane systematic review of cough medicines con-
cluded that there was no evidence for or against cough
medicines for URTI-associated cough.6 Previous trials of
cough medicines have been hampered by the recruit-
ment of small numbers of participants, the recruitment
of participants not representative of URTI-associated
cough, uncontrolled study design and the use of unval-
idated end points. We conducted a randomised clinical
trial that included validated cough outcome measures.
Our primary outcome measure, the VAS, is widely used
in studies of cough.15 We recruited participants with an
URTI-associated cough who were otherwise healthy and
seeking an antitussive medicine. Our participants were
unselected for the category of cough, and included a
broad range of participants with self-reported dry,
chesty and tickly cough. We conducted a large study,
recruiting participants from 18 sites. This is the ﬁrst
study to recruit participants presenting to pharmacies,
and therefore the study population is more likely to
resemble the broader population seeking cough medi-
cines. There were few participants that dropped out of
the trial, and therefore our data completeness was
good. The efﬁcacy of the interventions was evaluated
with widely used and validated end points of cough
severity VAS and LCQ-acute HRQoL questionnaires.15 16
We conducted a controlled trial and the comparator
was a widely used OTC treatment. SL, which costs less
than many OTC medicines to purchase but like most
cough medicines, it lacks a strong evidence base. Its
efﬁcacy has not been compared with natural recovery,
placebo or to other cough medicines. The rate of
reduction of cough severity VAS associated with SL in
our study does appear to be greater than that reported
for natural recovery.12 The mechanism of action of SL
is poorly understood, but is thought to be related to a
demulcent effect and the hypersalivation resulting from
the sugary taste.11
There was a clinically signiﬁcant reduction in primary
end point cough severity VAS at day 4 in both groups.
However, CS1002 did not achieve the primary end point
of a greater reduction in cough severity at day 4 com-
pared with SL. There were, however, greater reductions
in secondary end points of sleep disruption and cough
frequency, and improvements in HRQoL associated with
CS1002 compared with SL. There was also a trend
favouring greater resolution of cough at day 4 with
CS1002 compared with SL, with a near doubling of the
proportion of participants whose cough had resolved.
This was supported by a post hoc analysis that found a
signiﬁcantly greater number of participants had discon-
tinued their medication due to resolution of cough by
day 4 (CS1002, 24.4% vs SL, 10.7%: p=0.02). The MID
for cough outcome measures of frequency VAS, sleep
disruption VAS and cough resolution have not been
reported in URTI-associated cough, and this should be
studied in future to facilitate the clinical interpretation
of data. CS1002 was well tolerated, and there were few
signiﬁcant AEs, including drowsiness. Drowsiness was
managed with dose reduction, and no participants dis-
continued the medication because of this symptom.
Participants were compliant with both medications, and
this was veriﬁed by counting the doses of medication
returned at the end of the study. The mechanism of
action of CS1002 is poorly understood. There are a
number of possibilities, which include a reduction in
cough reﬂex sensitivity,7 promotion of more restful sleep
and a demulcent action. CS1002 contains a cocoa-
ﬂavoured demulcent that is more viscous than most
available OTC cough medicines, and this may potentially
promote palatability.
Table 3 Adverse events (AEs)
CS1002
N=83
Simple linctus
N=79
AEs, n (%)
Total
N (%)
Total
N (%)
Number of participants with
an AE
17 (20.5) 21 (27.6)
Nervous system disorders 7 (8.4) 10 (13.2)
Headache 5 (6.0) 9 (11.8)
Dizziness 1 (1.2) 2 (2.6)
Respiratory, thoracic and
mediastinal disorders
8 (9.6) 9 (11.8)
Oropharyngeal pain 2 (2.4) 4 (5.3)
Cough 2 (2.4) 3 (3.9)
Productive cough 3 (3.6) 1 (1.3)
Dyspnoea 0 (0.0) 2 (2.6)
Gastrointestinal disorders 5 (6.0) 2 (2.6)
Diarrhoea 3 (3.6) 0 (0.0)
Abdominal pain upper 2 (2.4) 0 (0.0)
General disorders and
administration site conditions
0 (0.0) 5 (6.6)
Pain 0 (0.0) 3 (3.9)
Fever 0 (0.0) 2 (2.6)
Infections and infestations 1 (1.2) 2 (2.6)
Lower respiratory tract
infection
0 (0.0) 2 (2.6)
Treated set population. AEs reported for >1 participant.
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There are a number of important limitations with our
study. We did not use a placebo comparator, and the
study was not double-blinded. The limitations of a single-
blinded study were reduced by informing the partici-
pants that they were going to receive a cough medicine,
but not the characteristics of the medicine. The investi-
gators were blinded to the study because both medicines
were contained in identical packaging, and participants
were instructed to start their medication outside the
pharmacy or GP clinic. We used SL as the comparator
since this is a widely used cough treatment. It is possible
that there may have been greater differences in efﬁcacy
outcome measures if we had used an inactive placebo.
Another option for comparator that should be consid-
ered in future studies is the demulcent used in CS1002.
It is likely that there was also signiﬁcant natural recovery
in our study. Our data highlight the difﬁculty in evaluat-
ing cough medicines in a rapidly resolving condition.
We do not know whether the cough at study entry was
worsening or improving and this could have impacted
on our ﬁndings. We were short of our recruitment
target of 180 participants; we recruited 163 participants.
This was due to a delay in the start of the study, and con-
sequently a reduced time window for recruitment
during the cough and cold winter season. We think it is
unlikely that the slight under-recruitment of participants
would have altered our study conclusions. The reasons
for screen failures were not recorded for many patients,
particularly at busy pharmacy sites. The reasons were,
however, recorded for 2238 participants and suggest that
a large number of participants approached had duration
of cough >7 days. It is possible that the discontinuation
of medication could have reﬂected lack of efﬁcacy as
well as recovery. We did not investigate the cause of the
acute cough, and future studies should possibly assess
viruses, pertussis and bacterial causes. We did not assess
cough with objective outcome measures, such as cough
frequency monitoring.16 Recently, there have been sig-
niﬁcant advances in cough monitoring technology, and
this should be possible in future studies.17
In conclusion, the OTC cough medicine CS1002 did
not achieve a signiﬁcant reduction in the primary end
point cough severity, but it was associated with a greater
reduction in cough frequency and sleep disruption, and
increased resolution of cough leading to early discon-
tinuation of medication and improved HRQoL com-
pared with comparator SL. Further studies should
investigate the impact of natural recovery and placebo
on cough outcome measures to facilitate the optimal
study protocol in URTI-associated cough.
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